The αvβ6 integrin specific virotherapy, Ad5
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
06
05
2024
accepted:
25
09
2024
revised:
21
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
aheadofprint
Résumé
Pancreatic ductal adenocarcinoma (PDAC) represent an unmet clinical need. Approximately 90% of PDACs express high levels of αvβ6 integrin. We have previously described Ad5 Here, we incorporate suicide genes FCY1 and FCU1 encoding for cytosine deaminase (CDase) or a combination of CDase and UPRTase, capable of catalysing a non-toxic prodrug, 5-FC into the chemotherapeutic 5-FU and downstream metabolites, into replication-deficient Ad5 and Ad5 We show that Ad5 Taken together these data provide the preclinical rationale for combined Ad5
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) represent an unmet clinical need. Approximately 90% of PDACs express high levels of αvβ6 integrin. We have previously described Ad5
METHODS
METHODS
Here, we incorporate suicide genes FCY1 and FCU1 encoding for cytosine deaminase (CDase) or a combination of CDase and UPRTase, capable of catalysing a non-toxic prodrug, 5-FC into the chemotherapeutic 5-FU and downstream metabolites, into replication-deficient Ad5 and Ad5
RESULTS
RESULTS
We show that Ad5
CONCLUSION
CONCLUSIONS
Taken together these data provide the preclinical rationale for combined Ad5
Identifiants
pubmed: 39369056
doi: 10.1038/s41416-024-02869-3
pii: 10.1038/s41416-024-02869-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK (CRUK)
ID : C7838/A25173
Organisme : Cancer Research UK (CRUK)
ID : C36442/A27838
Informations de copyright
© 2024. The Author(s).
Références
Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14:141.
pubmed: 31395068
doi: 10.1186/s13014-019-1345-6
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:16022.
pubmed: 27158978
doi: 10.1038/nrdp.2016.22
Bourgeois-Daigneault M-C, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10:eaao1641.
pubmed: 29298865
doi: 10.1126/scitranslmed.aao1641
Cunliffe TG, Bates EA, Parker AL. Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers. 2020;12:3327.
pubmed: 33187160
doi: 10.3390/cancers12113327
Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res. 2010;16:2540–9.
pubmed: 20388844
doi: 10.1158/1078-0432.CCR-09-2974
Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, et al. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015;137:978–90.
pubmed: 25604186
doi: 10.1002/ijc.29442
Raki M, Särkioja M, Desmond RA, Chen DT, Bützow R, Hemminki A, et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol. 2008;108:166–72.
pubmed: 17950450
doi: 10.1016/j.ygyno.2007.09.013
Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108:2554–61.
pubmed: 16788098
doi: 10.1182/blood-2006-04-008532
Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses. 2015;7:6009–42.
pubmed: 26610547
pmcid: 4664994
doi: 10.3390/v7112923
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–3.
pubmed: 9036860
doi: 10.1126/science.275.5304.1320
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309–19.
pubmed: 8477447
doi: 10.1016/0092-8674(93)90231-E
Coyne CB, Bergelson JM. CAR: a virus receptor within the tight junction. Adv drug Deliv Rev. 2005;57:869–82.
pubmed: 15820557
doi: 10.1016/j.addr.2005.01.007
Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397–409.
pubmed: 18267072
doi: 10.1016/j.cell.2008.01.016
Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, et al. Ad5(NULL)-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clin Cancer Res. 2018;24:4215–24.
pubmed: 29798908
doi: 10.1158/1078-0432.CCR-18-1089
Davies JA, Marlow G, Uusi-Kerttula HK, Seaton G, Piggott L, Badder LM, et al. Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20. Viruses. 2021;13:864.
pubmed: 34066836
doi: 10.3390/v13050864
Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, et al. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol. 2019;249:332–42.
pubmed: 31259422
doi: 10.1002/path.5320
Steiger K, Schlitter A-M, Weichert W, Esposito I, Wester H-J, Notni J. Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Mol Imaging. 2017;16:1536012117709384.
pubmed: 28627323
doi: 10.1177/1536012117709384
Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.
pubmed: 12724731
doi: 10.1038/nrc1074
Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002;129:2447–57.
pubmed: 11973276
doi: 10.1242/dev.129.10.2447
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8.
pubmed: 11751630
pmcid: 312845
doi: 10.1101/gad.943001
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847–60.
pubmed: 15607980
doi: 10.1016/j.cell.2004.11.004
Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol. 2007;37:43–53.
pubmed: 17171761
doi: 10.1002/eji.200636745
Salvador-Barbero B, Álvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, et al. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020;37:340–53.e6.
pubmed: 32109375
doi: 10.1016/j.ccell.2020.01.007
Hill W, Zaragkoulias A, Salvador-Barbero B, Parfitt GJ, Alatsatianos M, Padilha A, et al. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas. Curr Biol. 2021;31:2550–60.e5.
pubmed: 33891893
pmcid: 8231095
doi: 10.1016/j.cub.2021.03.094
Salvador-Barbero B, Alatsatianos M, Morton JP, Sansom OJ, Hogan C. Oncogenic KRAS cells use Wnt signalling and cell dormancy to override homeostatic cell elimination mechanisms in adult pancreas. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.02.13.579930v1 .
Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 2008;15:18–28.
pubmed: 17992203
doi: 10.1038/sj.cgt.7701098
Reeh M, Bockhorn M, Görgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109:1848–58.
pubmed: 24022195
pmcid: 3790165
doi: 10.1038/bjc.2013.509
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.
pubmed: 15894267
doi: 10.1016/j.ccr.2005.04.023
Boj Sylvia F, Hwang C-I, Baker Lindsey A, Chio Iok In C, Engle Dannielle D, Corbo V, et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell. 2015;160:324–38.
pubmed: 25557080
doi: 10.1016/j.cell.2014.12.021
Frappart P-O, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers. 2020;12:2750.
pubmed: 32987786
doi: 10.3390/cancers12102750
Clinton J, McWilliams-Koeppen P. Initiation, Expansion, and Cryopreservation of Human Primary Tissue-Derived Normal and Diseased Organoids in Embedded Three-Dimensional Culture. Curr Protoc Cell Biol. 2019;82:e66.
pubmed: 30265443
doi: 10.1002/cpcb.66
Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 2008;15:1361–71.
pubmed: 18480846
doi: 10.1038/gt.2008.82
Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, et al. Cowpox Virus: A New and Armed Oncolytic Poxvirus. Mol Ther Oncolytics. 2017;7:1–11.
pubmed: 28951885
doi: 10.1016/j.omto.2017.08.003
Carter ME, Hartkopf AD, Wagner A, Volmer LL, Brucker SY, Berchtold S, et al. A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front Mol Biosci. 2022;9:826302.
pubmed: 35223990
doi: 10.3389/fmolb.2022.826302
Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 2008;68:561–70.
pubmed: 18199553
doi: 10.1158/0008-5472.CAN-07-2307
Meecham A, Marshall JF. The ITGB6 gene: its role in experimental and clinical biology. Gene X. 2020;5:100023.
pubmed: 32550552
Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108:2241–51.
pubmed: 7673344
doi: 10.1242/jcs.108.6.2241
Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. Cancers. 2017;9:110.
pubmed: 28832494
doi: 10.3390/cancers9090110
Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, et al. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLOS Comput Biol. 2019;15:e1006596.
pubmed: 30629588
doi: 10.1371/journal.pcbi.1006596
Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8:1112–29.
pubmed: 29853643
pmcid: 6125219
doi: 10.1158/2159-8290.CD-18-0349
Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22:454–67. e6
pubmed: 29337182
doi: 10.1016/j.stem.2017.12.009
Huang L, Bockorny B, Paul I, Akshinthala D, Frappart PO, Gandarilla O, et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5:e135544.
pubmed: 32990680
pmcid: 7710298
doi: 10.1172/jci.insight.135544
Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine. 2020;56:102786.
pubmed: 32460166
pmcid: 7251378
doi: 10.1016/j.ebiom.2020.102786
Rosellini A, Freer G, Quaranta P, Dovere V, Menichini M, Maggi F, et al. Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection. J Virol Methods. 2019;265:99–104.
pubmed: 30582939
doi: 10.1016/j.jviromet.2018.12.017
Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, et al. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers. 2021;13:440.
pubmed: 33503832
pmcid: 7865443
doi: 10.3390/cancers13030440
Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. αvβ6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer. J Histochem Cytochem. 2002;50:1371–9.
pubmed: 12364570
doi: 10.1177/002215540205001010
Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, et al. Integrin ανβ6 Acts as a Prognostic Indicator in Gastric Carcinoma. Clin Oncol. 2008;20:61–6.
doi: 10.1016/j.clon.2007.09.008